SELLAS Life Sciences Group Past Earnings Performance
Past criteria checks 0/6
SELLAS Life Sciences Group's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 12.2% per year.
Key information
-9.7%
Earnings growth rate
77.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -12.2% |
| Return on equity | -1,182.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SELLAS Life Sciences Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -34 | 14 | 21 |
| 31 Mar 24 | 0 | -36 | 14 | 22 |
| 31 Dec 23 | 0 | -37 | 14 | 24 |
| 30 Sep 23 | 0 | -38 | 14 | 25 |
| 30 Jun 23 | 0 | -36 | 14 | 23 |
| 31 Mar 23 | 0 | -36 | 14 | 23 |
| 31 Dec 22 | 1 | -41 | 13 | 20 |
| 30 Sep 22 | 1 | -39 | 12 | 18 |
| 30 Jun 22 | 1 | -39 | 11 | 18 |
| 31 Mar 22 | 3 | -35 | 11 | 16 |
| 31 Dec 21 | 8 | -21 | 11 | 16 |
| 30 Sep 21 | 10 | -18 | 12 | 15 |
| 30 Jun 21 | 10 | -15 | 12 | 13 |
| 31 Mar 21 | 8 | -15 | 11 | 12 |
| 31 Dec 20 | 2 | -17 | 10 | 9 |
| 30 Sep 20 | 0 | -21 | 9 | 9 |
| 30 Jun 20 | 0 | -28 | 9 | 8 |
| 31 Mar 20 | 0 | -27 | 10 | 7 |
| 31 Dec 19 | 0 | -28 | 10 | 7 |
| 30 Sep 19 | 0 | -34 | 11 | 9 |
| 30 Jun 19 | 0 | -32 | 10 | 9 |
| 31 Mar 19 | 0 | -36 | 12 | 9 |
| 31 Dec 18 | 0 | -41 | 13 | 9 |
| 30 Sep 18 | 0 | -37 | 10 | 6 |
| 30 Jun 18 | 0 | -32 | 12 | 5 |
| 31 Mar 18 | 0 | -30 | 11 | 6 |
| 31 Dec 17 | 0 | -24 | 9 | 6 |
| 30 Sep 17 | 0 | -21 | 11 | 9 |
| 30 Jun 17 | 0 | -23 | 10 | 12 |
| 31 Mar 17 | 0 | -20 | 6 | 12 |
| 31 Dec 16 | 0 | -18 | 5 | 11 |
Quality Earnings: RXK3 is currently unprofitable.
Growing Profit Margin: RXK3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RXK3 is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare RXK3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RXK3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: RXK3 has a negative Return on Equity (-1182.25%), as it is currently unprofitable.